Covidien (NYSE:COV) said today that it’s launching its Emprint soft tissue ablation system, aiming at the market for inoperable liver cancers.
The Mansfield, Mass.-based medical device company said the Emprint device, which uses Covidien’s Thermosphere technology, is designed to ablate diseased soft tissue in the liver, lung and kidney, including non-resectable liver tumors. The device is not intended for use in cardiac ablation procedures, Covidien said.
"Covidien is dedicated to improving patient safety and simplifying procedural options, and this innovative technology enables physicians to deliver precise ablation directly to soft tissue, including liver tumors," early technologies president Chuck Brynelsen said in prepared remarks. "By providing predictable spherical ablation zones, this technology gives physicians more choices in terms of approach, further simplifying needle placement and saving planning and procedure time."
Covidien won 510(k) clearance from the FDA for the Emprint device in April and said today that it’s met all the requirements for CE Mark approval in the European Union.
"The company expects to fully launch the Emprint system in the United States and the European Union during the current quarter," according to a press release.